PTEN Loss in Prostate Cancer and Its Impact on Outcomes
Author Information
Author(s): McCall P, Witton C J, Grimsley S, Nielsen K V, Edwards J
Primary Institution: University of Glasgow
Hypothesis
Is PTEN loss associated with clinical outcome measures in human prostate cancer?
Conclusion
The study found that loss of PTEN expression is associated with disease progression and poorer survival outcomes in prostate cancer.
Supporting Evidence
- PTEN gene deletion was observed in 23% of hormone-sensitive tumors and increased to 52% in hormone-refractory tumors.
- Low levels of cytoplasmic PTEN were associated with shorter time to relapse.
- Loss of nuclear PTEN expression was associated with shorter overall survival.
Takeaway
This study looked at how losing a specific gene called PTEN affects prostate cancer. They found that when this gene is lost, patients tend to do worse.
Methodology
The study used fluorescent in situ hybridisation and immunohistochemistry to analyze PTEN gene deletion and protein expression in matched hormone-sensitive and hormone-refractory prostate tumors.
Potential Biases
Potential bias due to the retrospective selection of patients and the reliance on archived tissue samples.
Limitations
The study's findings may not be generalizable due to the small sample size and the retrospective nature of the analysis.
Participant Demographics
Patients were diagnosed with locally advanced or metastatic prostate cancer, with a median age of 70 years.
Statistical Information
P-Value
P=0.044
Confidence Interval
95% CI 0.27–0.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website